Loading...
Oxaliplatin is increasingly the standard agent to combine with 5-fluorouracil to treat a broad range of gastrointestinal cancers, including colorectal, pancreaticobiliary, and esophagogastric cancers. However, both acute and chronic sensory neurotoxicity are problematic with this agent, and chronic neurotoxicity is dose limiting in oxaliplatin therapy.
To determine whether prophylactic administration of calcium and magnesium reduces oxaliplatin neurotoxicity, investigators conducted a phase III, multicenter, randomized, double-blind, placebo-controlled trial involving 353 patients with colon cancer receiving FOLFOX (fluorouracil, leucovorin, and oxaliplatin) as adjuvant therapy or as treatment for metastatic disease. Patients were randomized…